Supreme Court Unanimously Rules Against Induced Infringement Claim in Hikma v. Amarin, Clarifying Standards for Generic Drug Labeling

The Supreme Court delivered a unanimous ruling in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., No. 24-889, resolving a pivotal dispute over the standard for induced patent infringement under 35 U.S.C. § 271(b). The Court held that Amarin, the reference drug sponsor, failed to state a claim against Hikma, a generic manufacturer, for actively inducing infringement of Amarin’s method-of-use patents.

The case centered on Amarin’s drug Vascepa (icosapent ethyl), initially approved by the FDA in 2012 to treat severe hypertriglyceridemia (the "SH indication"). In 2019, the FDA granted a second approval for Vascepa to reduce cardiovascular risk in patients with hypertriglyceridemia already on statins (the "CV indication"), which was covered by Amarin’s method-of-use patents.

Hikma filed an abbreviated new drug application (ANDA) for generic icosapent ethyl with a "skinny label" that excluded the patented CV indication but included the unpatented SH indication. The FDA approved Hikma’s generic in 2020, assigning it an "AB" rating indicating therapeutic equivalence to Vascepa when used as labeled.

Amarin sued Hikma in the District of Delaware, alleging that Hikma actively induced infringement by encouraging use of the generic drug for the patented CV indication. The District Court dismissed the claim for failure to state a claim, finding Hikma’s statements did not constitute active inducement. The Federal Circuit reversed, holding it plausible that Hikma’s statements could be read as instructions to infringe.

The Supreme Court granted certiorari to clarify the standard for pleading induced infringement at the motion-to-dismiss stage under Rule 12(b)(6) and the plausibility standard from Bell Atlantic Corp. v. Twombly.

Justice Jackson, writing for the unanimous Court, emphasized that induced infringement requires "purposeful, culpable expression and conduct"—affirmative steps designed to cause infringement—not mere knowledge or passive conduct. The Court rejected the Federal Circuit’s approach that focused on whether statements could be interpreted by physicians as instructions to infringe.

The Court noted that all states permit or require substitution of brand-name drugs with generics, meaning generic manufacturers expect some infringing use. However, mere knowledge of potential infringement is insufficient to impose liability.

First, several statements had obvious alternative explanations grounded in compliance with federal law and industry practice. For example, the skinny label included information about statin-taking patients because FDA regulations require generic labels to mirror the reference product except for patented uses. Describing the product as "generic Vascepa" or "generic equivalent" reflected standard industry terminology. The Court declined to penalize Hikma for adhering to legal and industry norms.

Second, the Court held that omissions or failures to mention patented uses—such as the skinny label’s omission of the CV indication or press releases not highlighting the limited approved use—do not constitute active inducement. Imposing liability based on omissions would risk holding ordinary merchants liable for downstream misuse of their products.

Third, the Court found other statements too vague to support inducement. The patient information leaflet’s cardiovascular warnings, the website’s broad therapeutic category listing, and press releases’ sales figures were insufficiently specific or targeted to induce infringement. The Court analogized broad therapeutic categories to describing a leukemia drug as a "cancer drug," which is not an instruction to infringe.

Importantly, the Court clarified that inducement need not be express; implicit encouragement can suffice if it is clear and affirmative to the relevant audience. However, the plaintiff must plausibly allege that the defendant took active steps to encourage infringement, not merely that infringement might result from the defendant’s conduct.

This ruling overturns a recent Federal Circuit trend and provides critical guidance for generic drug manufacturers using skinny labels. It underscores that compliance with FDA labeling requirements and standard industry practices cannot be the basis for inducement liability.

While the Court resolved the pleading standard, it left open the question of what facts would meet the plausibility threshold on remand. Plaintiffs alleging induced infringement must now demonstrate intentional, affirmative encouragement of infringement rather than relying on ambiguous statements or omissions.

The decision has significant implications for Hatch-Waxman litigation and patent enforcement strategies, clarifying that active inducement requires purposeful conduct designed to cause infringement, not passive compliance or indirect effects.